Search

Your search keyword '"Catherine Ann, Byrnes"' showing total 3 results
Start Over Author "Catherine Ann, Byrnes"
3 results on '"Catherine Ann, Byrnes"'

1. Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand

Author

Adèle Coriati, Xiayi Ma, Jenna Sykes, Sanja Stanojevic, Rasa Ruseckaite, Lydie Lemonnier, Clémence Dehillotte, Jan Tate, Catherine Ann Byrnes, Scott C Bell, Pierre Regis Burgel, and Anne L Stephenson

Subjects
Pulmonary and Respiratory Medicine
Abstract

BackgroundLife expectancy for people with cystic fibrosis (CF) varies considerably both within and between countries. The objective of this study was to compare survival among countries with single-payer healthcare systems while accounting for markers of disease severity.MethodsThis cohort study used data from established national CF registries in Australia, Canada, France and New Zealand from 2015 to 2019. Median age of survival for each of the four countries was estimated using the Kaplan-Meier method. A Cox proportional hazards model was used to compare risk of death between Canada, France and Australia after adjusting for prognostic factors. Due to low number of deaths, New Zealand was not included in final adjusted models.ResultsBetween 2015 and 2019, a total of 14 842 people (3537 Australia, 4434 Canada, 6411 France and 460 New Zealand) were included. The median age of survival was highest in France 65.9 years (95% CI: 59.8 to 76.0) versus 53.3 years (95% CI: 48.9 to 59.8) for Australia, 55.4 years (95% CI: 51.3 to 59.2) for Canada and 54.8 years (95% CI: 40.7 to not available) for New Zealand. After adjusting for individual-level factors, the risk of death was significantly higher in Canada (HR 1.85, 95% CI: 1.48 to 2.32; pInterpretationWe observed significantly higher survival in France compared with countries with single-payer healthcare systems. The median age of survival in France exceeded 60 years of age despite having the highest proportion of underweight patients which may be due to differences in availability of transplant.

Published
2022

2. Three-weekly doses of azithromycin for Indigenous infants hospitalised with bronchiolitis: A multicentre, randomised, placebo-controlled trial

Author

Gabrielle Britt McCallum, Peter S Morris, Keith eGrimwood, Carolyn eMaclennan, Andrew V White, Mark D Chatfield, Theo P Sloots, Ian M Mackay, Heidi eSmith-Vaughan, Clare C Mckay, Lesley A Versteegh, Nerida eJacobsen, Charmaine eMobberley, Catherine Ann Byrnes, and Anne B Chang

Subjects
Azithromycin, Bacteria, Bronchiolitis, Macrolides, Viruses, respiratory syncytial virus, Pediatrics, RJ1-570
Abstract

Background Bronchiolitis is a major health burden in infants globally, particularly among Indigenous populations. It is unknown if 3-weeks of azithromycin improve clinical outcomes beyond the hospitalisation period. In an international, double-blind randomised controlled trial, we determined if 3-weeks of azithromycin, improved clinical outcomes in Indigenous infants hospitalised with bronchiolitis. Methods Infants aged ≤24-months were enrolled from three centres and randomised to receive three once-weekly doses of either azithromycin (30mg/kg) or placebo. Nasopharyngeal swabs were collected at baseline and 48-hours later. Primary endpoints were hospital length of stay (LOS) and duration of oxygen supplementation monitored every 12-hours until judged ready for discharge. Secondary outcomes were: day-21 symptom/signs, respiratory rehospitalisations within 6-months post-discharge and impact upon nasopharyngeal bacteria and virus shedding at 48-hours. Results Two-hundred-and-nineteen infants were randomised (n=106 azithromycin, n=113 placebo). No significant between-group differences were found for LOS (median 54-hours for each group, difference=0-hours, 95%CI: -6, 8; p=0.8), time receiving oxygen (azithromycin=40-hours, placebo=35-hours, group difference=5-hours, 95%CI: -8, 11; p=0.7), day-21 symptom/signs or rehospitalisation within 6-months (azithromycin n=31, placebo=25 infants, p=0.2). Azithromycin reduced nasopharyngeal bacterial carriage (between-group difference 0.4 bacteria/child, 95%CI: 0.2, 0.6; p

Published
2015
Full Text
View/download PDF

3. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age

Author

Catherine Ann, Byrnes, Suzanna, Vidmar, Joyce L, Cheney, John B, Carlin, David S, Armstrong, Peter J, Cooper, Keith, Grimwood, Marj, Moodie, Colin F, Robertson, Margaret, Rosenfeld, Harm A, Tiddens, Claire E, Wainwright, and Lauren, Mott

Subjects
Lung Diseases, Male, Pulmonary and Respiratory Medicine, Spirometry, medicine.medical_specialty, Cystic Fibrosis, Exacerbation, Respiratory Infection, Lung injury, Bronchoalveolar Lavage, 03 medical and health sciences, 0302 clinical medicine, Forced Expiratory Volume, 030225 pediatrics, Internal medicine, medicine, Humans, Prospective Studies, Prospective cohort study, Lung, Bronchiectasis, medicine.diagnostic_test, business.industry, Incidence, Infant, Newborn, Infant, Respiratory infection, Antibiotic Prophylaxis, Prognosis, medicine.disease, Anti-Bacterial Agents, 3. Good health, Hospitalization, Bronchoalveolar lavage, medicine.anatomical_structure, 030228 respiratory system, Child, Preschool, Physical therapy, Female, Radiography, Thoracic, Tomography, X-Ray Computed, business, Follow-Up Studies, New Zealand
Abstract

Background Newborn screening allows novel treatments for cystic fibrosis (CF) to be trialled in early childhood before irreversible lung injury occurs. As respiratory exacerbations are a potential trial outcome variable, we determined their rate, duration and clinical features in preschool children with CF; and whether they were associated with growth, lung structure and function at age 5 years. Methods Respiratory exacerbations were recorded prospectively in Australasian CF Bronchoalveolar Lavage trial subjects from enrolment after newborn screening to age 5 years, when all participants underwent clinical assessment, chest CT scans and spirometry. Results 168 children (88 boys) experienced 2080 exacerbations, at an average rate of 3.66 exacerbations per person-year; 80.1% were community managed and 19.9% required hospital admission. There was an average increase in exacerbation rate of 9% (95% CI 4% to 14%; p

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results